Head and neck surgeons are commonly faced with surgical patients who have underlying medical problems requiring antithrombotic therapy. It is difficult to achieve a balance between minimizing the risk of thromboembolism and hemorrhage in the perioperative period. Data from randomized, controlled trials are limited, and procedurespecific bleed rates are also difficult to pinpoint. The decision is made more difficult when patients with moderate-to-high risk for thromboembolic events undergo procedures that are high risk for bleeding. This is true for many head and neck oncologic surgeries. Furthermore, although elective procedures may be delayed for optimization of antithrombotic medication, emergent procedures cannot. Head and neck surgery often represents the most challenging of all these circumstances, given the potential risk of airway compromise from bleeding after head and neck surgery.
K E Y W O R D Santicoagulants, antithrombotics, guidelines, head and neck cancer, perioperative
| I NT ROD UCTI ONOpinions can differ among medical specialists, surgeons, and anesthesiologists regarding perioperative antithrombotic management. The purpose of this article is to review contemporary guidelines, based on the available literature, for management of antithrombotic medications in the perioperative period specific to head and neck oncologic surgery. Although general guidelines are helpful, it should be stressed that clear lines of communication among providers are essential to achieve a "right balance," especially in cases that do not fit neatly within existing guidelines.